Vitamin D’s Secret Weapon: A Novel Attack on Pancreatic Cancer

Researchers at the Dana-Farber Cancer Institute have advanced a concept originating from the Salk Institute, evaluating its potential in human subjects. The hypothesis posited that stimulating the vitamin D receptor could modify the protective matrix surrounding pancreatic tumors, rendering this notoriously challenging malignancy more susceptible to therapeutic interventions.

The investigation, documented in the May 25, 2026, edition of Nature Cancer, involved participants diagnosed with previously untreated metastatic pancreatic cancer. These individuals received a standard chemotherapy regimen, supplemented in some cases with paricalcitol, a compound analogous to vitamin D that has already received FDA clearance for other medical applications. Findings indicated that the concurrent administration of paricalcitol, whether orally or intravenously, proved safe and effectively diminished the activation of fibroblasts within the tumor’s immediate vicinity, thereby substantiating the preclinical findings from Salk.

While the primary objective of this trial was not to ascertain treatment efficacy, investigators observed encouraging trends, including enhanced chemotherapy responses and extended progression-free survival at the one-year mark among participants who were administered paricalcitol in conjunction with chemotherapy. Furthermore, an analysis revealed that individuals exhibiting high levels of vitamin D receptor expression who also received paricalcitol experienced the most prolonged overall survival.

This research represents a groundbreaking strategy for addressing therapeutic resistance in pancreatic cancer. By harnessing the body’s intrinsic systems through vitamin D analogs to mitigate fibrotic and inflammatory responses, we can create an environment where other treatments can function more effectively.”

Ronald Evans, PhD, Co-author of the study, Professor, and holder of the March of Dimes Chair in Molecular and Developmental Biology at Salk

How did foundational research lead to this clinical trial?

Dr. Evans was instrumental in the discovery of the nuclear receptor superfamily, a vital class of molecules that encompasses the vitamin D receptor. Upon activation by specific hormones, vitamins, or lipids, these nuclear receptors modulate gene expression, thereby governing cellular activities. Currently, a significant proportion of FDA-approved pharmaceuticals operate by targeting nuclear receptors.

Subsequent investigations by Dr. Evans and his colleagues elucidated the role of the vitamin D receptor in regulating fibroblasts within the liver and pancreas in preclinical models. Fibroblasts, comprising connective tissue, are responsible for constructing the dense matrix that frequently encases pancreatic and other types of tumors.

These seminal studies demonstrated that the vitamin D receptor is highly expressed in select populations of tissue-resident fibroblasts and plays a crucial role in preserving tissue integrity and stability. The Evans research group further established that the progression of liver fibrosis and pancreatitis could be inhibited by synthetic vitamin D analogs, such as paricalcitol, which are engineered to circumvent the body’s natural degradation mechanisms for vitamin D.

Given that an pronounced fibrotic response is a characteristic feature of pancreatic tumors, the Evans team subsequently examined the impact of these therapeutic agents on the pancreatic cancer microenvironment—the cellular milieu surrounding the tumor. They observed, with considerable surprise, that in pancreatic cancer models, vitamin D analogs could effectively reverse the activation of cancer-associated fibroblasts, consequently enhancing responses to chemotherapy.

These earlier discoveries provided one of the initial demonstrations of a novel therapeutic paradigm for pancreatic cancer: the reprogramming of the supportive cellular environment that not only surrounds but also shields pancreatic cancer cells.

From bench to bedside: What did the clinical trial do and what did it find?

Building upon these fundamental insights from Salk and in collaboration with Dr. Evans’ team, Brian Wolpin, MD, MPH, and Kimberly Perez, MD, at the Dana-Farber Cancer Institute, spearheaded a randomized, safety-focused clinical study investigating the effects of vitamin D analogs in pancreatic cancer.

In this trial, 36 participants diagnosed with previously untreated metastatic pancreatic cancer were allocated to receive standard chemotherapy (gemcitabine combined with nab-paclitaxel), in addition to either a placebo, intravenous paricalcitol, or oral paricalcitol. Paricalcitol is an FDA-approved medication utilized for the prevention and treatment of secondary hyperparathyroidism in individuals with chronic kidney disease.

The primary objective of the trial was to evaluate the safety profile of incorporating paricalcitol into the chemotherapy regimen. Overall, paricalcitol was administered safely alongside chemotherapy. However, five out of twelve participants receiving oral paricalcitol experienced elevated blood calcium levels, a condition that was effectively managed through standard dose adjustments.

A significant secondary objective of this trial was to ascertain whether any molecular or cellular alterations occurred in patients undergoing paricalcitol treatment. To achieve this, sequential patient biopsies were procured at the screening phase and subsequently after four to six weeks of therapy. Advanced multiplex immunofluorescence and spatial transcriptomic techniques were employed to analyze these samples, enabling a detailed examination of changes within tumor and microenvironment cell populations. The analysis revealed that paricalcitol led to a reduction in fibroblast activation within tumors (without significantly altering their total number) and an increase in the infiltration of T cells, a type of immune cell typically excluded from tumor sites. These findings confirmed paricalcitol’s promise as a therapy capable of remodeling the tumor microenvironment.

Although the study was not designed for comparative efficacy assessment or direct outcome measurement, the researchers observed notable differences. Partial responses to therapy were more prevalent in the group receiving paricalcitol (10 of 24 participants, or 42%) compared to the placebo group (1 of 12 participants, or 9%). Furthermore, a greater proportion of patients who received paricalcitol remained progression-free at the one-year mark (five patients) compared to the placebo cohort (none).

The researchers also noted variations in the levels of vitamin D receptor expression within patients’ tumors. Moreover, they discovered a correlation between vitamin D receptor levels and treatment outcomes: patients with high vitamin D receptor expression who received paricalcitol exhibited superior responses to chemotherapy and achieved the longest overall survival duration post-treatment.

Why is this important?

Pancreatic cancer continues to present formidable challenges in treatment. While standard chemotherapy can provide disease stabilization for some individuals, overall prognoses remain unfavorable, with the tumor microenvironment widely implicated as a contributor to therapeutic resistance. Pancreatic tumors are frequently encased in dense, fibroblast-rich connective tissue, forming a physical barrier that impedes the delivery of therapeutic agents and cultivates an immunosuppressive milieu.

What’s next?

The outcomes of this trial have paved the way for larger clinical studies aimed at evaluating the impact of combining vitamin D analogs with chemotherapy or other cancer treatments on survival rates. Additionally, future research will focus on determining whether baseline vitamin D receptor expression can serve as a dependable biomarker for predicting patient responses to combination therapies, including those involving vitamin D analogs.

“This study marks a significant advancement in the utilization of a vitamin D analog as a stromal remodeling therapy capable of overcoming therapeutic resistance in pancreatic cancer,” stated Dr. Perez. “It is built upon foundational basic science research conducted at the Salk Institute, validates those preclinical findings in a patient population, and provides a clear direction for future investigations that could ultimately establish a new standard of care.”